|

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

RECRUITINGPhase 2Sponsored by National Medical Research Radiological Centre of the Ministry of Health of Russia
Actively Recruiting
PhasePhase 2
SponsorNational Medical Research Radiological Centre of the Ministry of Health of Russia
Started2025-04-15
Est. completion2028-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06984146

Summary

The aim of the current trial is to evaluate the efficacy and safety of flat-dose nivolumab (40 mg) in combination with AVD in the management of patients with newly diagnosed advanced classic Hodgkin Lymphoma

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Newly-diagnosed histologically verified advanced stage (IIB-IV as per GHSG) classic Hodgkin lymphoma
2. No past history of autoimmune disease
3. Age \> 18 years
4. Ejection fraction \> 50%
5. ECOG 0-4

Exclusion Criteria:

1. Organ failure (e.g. creatinine \> 2x ULN; ALT or AST \> 5x ULN; bilirubin \> 2x ULN; hemodynamic instability; respiratory failure \> Grade 1)
2. Uncontrolled infection
3. Pregnancy
4. Inability to sign informed consent

Conditions2

CancerHodgkin Lymphoma, Adult

Interventions4

DacarbazineDoxorubicinNivolumabVinblastine

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.